Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in breast cancer with bone metastases (RADAR)
NCT00466102Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2006
- Primary completion
- Dec 2010
- Countries
- 1
- Sponsor
- GBG Forschungs
- Drugs
- everolimus
- Conditions
- breast cancer
01
Overview
Phase 2, randomised, double-blind trial of everolimus in breast cancer, sponsored by GBG Forschungs. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
The purpose of this study is to determine wether RAD001 can inhibit growth of tumour cells and/or stop the formation and activity of bone degrading osteoclasts.
Beyond the preview
Go deeper on NCT00466102.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466102.